New
York
|
|
14-1702188
|
(State
or other jurisdiction of incorporation or
organization)
|
|
(I.R.S.
Employer Identification No.)
|
Large
accelerated filer
|
☐
|
Accelerated
filer
|
☐
|
Non-accelerated
filer
|
☐
|
Smaller
reporting company
|
☑
|
PART I – FINANCIAL INFORMATION
|
PAGE
|
|
|
Item
1. Condensed Financial
Statements
|
3
|
|
|
Condensed Balance
Sheets as of March 31, 2018 (unaudited) and December 31,
2017
|
3
|
|
|
Condensed Unaudited
Statements of Operations for the three months ended March 31, 2018
and March 31, 2017
|
4
|
|
|
Condensed Unaudited
Statements of Cash Flows for the three months ended March 31, 2018
and March 31, 2017
|
5
|
|
|
Notes to Condensed
Financial Statements (unaudited)
|
6
|
|
|
Item
2. Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
13
|
|
|
Item
3. Quantitative and
Qualitative Disclosures About Market Risk
|
16
|
|
|
Item
4. Controls and
Procedures
|
16
|
|
|
PART II – OTHER INFORMATION
|
|
|
|
Item
1. Legal
Proceedings
|
17
|
|
|
Item
1A. Risk
Factors
|
17
|
|
|
Item
2. Unregistered Sales
of Equity Securities and Use of Proceeds
|
17
|
|
|
Item 3.
Defaults Upon
Senior Securities
|
17
|
|
|
Item
4. Mine Safety
Disclosures
|
17
|
|
|
Item
5. Other
Information
|
17
|
|
|
Item
6. Exhibits
|
17
|
|
|
Signatures
|
18
|
|
March 31,
|
December 31,
|
|
2018
|
2017
|
ASSETS
|
(Unaudited)
|
|
Current
assets
|
|
|
Cash and cash
equivalents
|
$92,000
|
$36,000
|
Accounts
receivable, net of allowance for doubtful accounts of $51,000 at
March 31, 2018 and $52,000 at December 31, 2017
|
421,000
|
348,000
|
Inventory, net of
allowance of $521,000 at March 31, 2018 and $500,000 at December
31, 2017
|
1,388,000
|
1,473,000
|
Prepaid expenses
and other current assets
|
61,000
|
97,000
|
Total current
assets
|
1,962,000
|
1,954,000
|
|
|
|
Property, plant and
equipment, net
|
774,000
|
792,000
|
Patents,
net
|
113,000
|
109,000
|
Other
assets
|
21,000
|
21,000
|
Deferred finance
costs – line of credit, net
|
7,000
|
15,000
|
Total
assets
|
$2,877,000
|
$2,891,000
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
Current
liabilities
|
|
|
Accounts
payable
|
$430,000
|
$374,000
|
Accrued expenses
and other current liabilities
|
354,000
|
311,000
|
Wages
payable
|
266,000
|
259,000
|
Line of
credit
|
492,000
|
446,000
|
Current portion of
long-term debt
|
237,000
|
87,000
|
Total current
liabilities
|
1,779,000
|
1,477,000
|
|
|
|
Other
liabilities/debt
|
16,000
|
19,000
|
Long-term debt, net
of current portion and deferred finance costs
|
704,000
|
772,000
|
Total
liabilities
|
2,499,000
|
2,268,000
|
|
|
|
COMMITMENTS AND
CONTINGENCIES
|
|
|
|
|
|
Stockholders'
equity:
|
|
|
Preferred stock;
par value $.01 per share; 5,000,000 shares authorized, none issued
and outstanding at March 31, 2018 and December 31,
2017
|
0
|
0
|
Common stock; par
value $.01 per share; 50,000,000 shares authorized; 29,932,770
issued and outstanding at March 31, 2018 and 29,782,770 issued and
outstanding as of December 31, 2017
|
299,000
|
298,000
|
Additional paid-in
capital
|
21,191,000
|
21,170,000
|
Accumulated
deficit
|
(21,112,000)
|
(20,845,000)
|
Total
stockholders’ equity
|
378,000
|
623,000
|
Total liabilities
and stockholders’ equity
|
$2,877,000
|
$2,891,000
|
|
For The Three Months Ended
|
|
|
March 31,
|
|
|
2018
|
2017
|
|
|
|
Net
sales
|
$1,041,000
|
$1,316,000
|
|
|
|
Cost of goods
sold
|
669,000
|
751,000
|
|
|
|
Gross
profit
|
372,000
|
565,000
|
|
|
|
Operating
expenses:
|
|
|
Research and
development
|
25,000
|
46,000
|
Selling and
marketing
|
161,000
|
196,000
|
General and
administrative
|
392,000
|
390,000
|
|
578,000
|
632,000
|
|
|
|
Operating
loss
|
(206,000)
|
(67,000)
|
|
|
|
Other income /
(expense):
|
|
|
Interest
expense
|
(71,000)
|
(65,000)
|
Other income,
net
|
10,000
|
0
|
|
(61,000)
|
(65,000)
|
|
|
|
Net
loss before tax
|
(267,000)
|
(132,000)
|
|
|
|
Income tax
expense
|
0
|
0
|
|
|
|
Net
loss
|
$(267,000)
|
$(132,000)
|
|
|
|
Basic
and diluted loss per common share
|
$(0.01)
|
$(0.00)
|
|
|
|
Weighted average
number of shares outstanding – basic
|
29,822,770
|
28,842,788
|
Weighted average
number of shares outstanding – diluted
|
29,822,770
|
28,842,788
|
|
For The Three Months Ended
|
|
|
March 31,
|
|
|
2018
|
2017
|
Cash flows from operating activities:
|
|
|
Net
loss
|
$(267,000)
|
$(132,000)
|
Adjustments
to reconcile net loss to net cash provided by operating
activities:
|
|
|
Depreciation
and amortization
|
20,000
|
22,000
|
Amortization
of debt issuance costs
|
33,000
|
31,000
|
Allowance
for doubtful accounts
|
(1,000)
|
0
|
Provision
for slow moving and obsolete inventory
|
21,000
|
21,000
|
Share-based
payment expense
|
4,000
|
11,000
|
Changes
in:
|
|
|
Accounts
receivable
|
(72,000)
|
(55,000)
|
Inventory
|
64,000
|
58,000
|
Prepaid
expenses and other current assets
|
36,000
|
29,000
|
Accounts
payable
|
56,000
|
0
|
Accrued
expenses and other current liabilities
|
43,000
|
(20,000)
|
Wages
payable
|
7,000
|
(12,000)
|
Net
cash used in operating activities
|
(56,000)
|
(47,000)
|
|
|
|
Cash flows from investing activities:
|
|
|
Patent
application costs
|
(6,000)
|
(9,000)
|
Net
cash used in investing activities
|
(6,000)
|
(9,000)
|
|
|
|
Cash flows from financing activities:
|
|
|
Proceeds
from / (payments on) debt financing
|
72,000
|
(75,000)
|
Proceeds
from lines of credit
|
1,095,000
|
1,403,000
|
Payments
on lines of credit
|
(1,049,000)
|
(1,292,000)
|
Net
cash provided by financing activities
|
118,000
|
36,000
|
|
|
|
Net change in cash and cash equivalents
|
56,000
|
(20,000)
|
Cash
and cash equivalents - beginning of period
|
36,000
|
156,000
|
|
|
|
Cash and cash equivalents - end of period
|
$92,000
|
$136,000
|
|
|
|
Supplemental disclosures of cash flow information
|
|
|
Cash
paid during period for interest
|
$36,000
|
$40,000
|
Consulting
expense prepaid with restricted stock
|
$25,000
|
$0
|
Debt
issuance cost paid with restricted stock
|
$18,000
|
$0
|
|
|
March
31,
2018
|
December
31,
2017
|
|
|
|
Raw
Materials
|
$1,004,000
|
$1,023,000
|
Work In
Process
|
407,000
|
403,000
|
Finished
Goods
|
498,000
|
547,000
|
Allowance for slow
moving and obsolete inventory
|
(521,000)
|
(500,000)
|
|
$1,388,000
|
$1,473,000
|
|
March
31,
2018
|
March
31,
2017
|
|
|
|
Warrants
|
2,000,000
|
2,060,000
|
Options
|
2,147,000
|
2,107,000
|
|
4,147,000
|
4,167,000
|
|
March
31,
2018
|
December
31,
2017
|
Loan and Security Agreement with Cherokee
Financial, LLC: 5 year note at an annual interest rate of 8%
plus a 1% annual oversight fee, interest only and oversight fee
paid quarterly with first payment being made on May 15, 2015,
annual principal reduction payment of $75,000 due each year
beginning on February 15, 2016, with a final balloon payment being
due on February 15, 2020. Loan is collateralized by a first
security interest in building, land and property.
|
$975,000
|
$1,050,000
|
Crestmark Line of Credit: 3 year line of
credit maturing on June 22, 2020 with interest payable at a
variable rate based on WSJ Prime plus 2% with a floor or 5.25%;
loan fee of 0.5% annually & monthly maintenance fee of 0.3% on
actual loan balance from prior month. Early termination fee of 2%
if terminated in year 2 or after (and prior to natural expiration).
Loan is collateralized by first security interest in receivables
and inventory and the all-in interest rate as of the date of this
report is 12.43%.
|
492,000
|
446,000
|
Crestmark Equipment Term Loan: 38 month
equipment loan related to the purchase of manufacturing equipment,
at an interest rate of WSJ Prime Rate plus 3%; or 7.75% as of the
date of this report.
|
28,000
|
31,000
|
Loan Agreement with Cherokee Financial
LLC: 1 year note at an annual interest rate of 12% paid
quarterly in arrears with first interest payment being due on May
15, 2018 and a balloon payment being due on February 15,
2019.
|
150,000
|
0
|
|
1,645,000
|
1,527,000
|
Less debt discount
& issuance costs (Cherokee Financial, LLC Loan)
|
(196,000)
|
(203,000)
|
Total debt,
net
|
1,449,000
|
1,324,000
|
|
|
|
Current
portion
|
729,000
|
533,000
|
Long-term portion,
net of current portion
|
$720,000
|
$791,000
|
|
First Quarter
2018
|
First Quarter
2017
|
||||
|
Shares
|
Weighted
Average Exercise Price
|
Aggregate
Intrinsic
Value as of
March
31, 2018
|
Shares
|
Weighted
Average Exercise Price
|
Aggregate
Intrinsic Value as of
March
31, 2017
|
Options outstanding
at beginning of year
|
2,147,000
|
$0.13
|
|
2,107,000
|
$0.13
|
|
Granted
|
0
|
NA
|
|
0
|
NA
|
|
Exercised
|
0
|
NA
|
|
0
|
NA
|
|
Cancelled/expired
|
0
|
NA
|
|
0
|
NA
|
|
Options outstanding
at end of year
|
2,147,000
|
$0.13
|
$15,000
|
2,107,000
|
$0.13
|
$15,000
|
Options exercisable
at end of year
|
2,022,000
|
$0.13
|
|
1,485,000
|
$0.13
|
|
|
First Quarter
2018
|
First Quarter
2017
|
||||
|
Shares
|
Weighted
Average Exercise Price
|
Aggregate
Intrinsic
Value as of
March
31, 2018
|
Shares
|
Weighted
Average Exercise Price
|
Aggregate
Intrinsic Value as of
March
31, 2017
|
Warrants
outstanding at beginning of year
|
2,060,000
|
$0.18
|
|
2,060,000
|
$0.18
|
|
Granted
|
0
|
NA
|
|
0
|
NA
|
|
Exercised
|
0
|
NA
|
|
0
|
NA
|
|
Cancelled/expired
|
60,000
|
$0.18
|
|
0
|
NA
|
|
Warrants
outstanding at end of year
|
2,000,000
|
$0.18
|
None
|
2,060,000
|
$0.18
|
None
|
Warrants
exercisable at end of year
|
2,000,000
|
$0.18
|
|
2,060,000
|
$0.18
|
|
Facility
|
|
Debtor
|
Balance
as of
March
31,
2018
|
Loan and Security
Agreement
|
|
Cherokee Financial,
LLC
|
$975,000
|
Revolving Line of
Credit
|
|
Crestmark
Bank
|
$492,000
|
Equipment
Loan
|
|
Crestmark
Bank
|
$28,000
|
Term
Loan
|
|
Cherokee Financial,
LLC
|
$150,000
|
Total
Debt
|
|
|
$1,645,000
|
|
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive
Officer/Chief Financial Officer
|
|
|
Certification
of the Chief Executive Officer/Chief Financial Officer pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
|
|
101
|
|
The
following materials from our Quarterly Report on Form 10-Q for the
quarter ended March 31, 2018, formatted in XBRL (Extensible
Business Reporting Language): (i) Condensed Balance Sheet, (ii)
Condensed Statements of Income (iii) Condensed Statements of Cash
Flows, and (iv) Notes to Condensed Financial
Statements.
|
|
AMERICAN BIO MEDICA
CORPORATION
|
|
|
|
(Registrant)
|
|
|
|
|
|
|
Dated: May 14,
2018
|
By:
|
/s/
Melissa
A. Waterhouse
|
|
|
|
Melissa A. Waterhouse |
|
|
|
Chief
Executive Officer (Principal Executive Officer)
Principal Financial
Officer
Principal
Accounting Officer |
|
Document And Entity Information - shares |
3 Months Ended | |
---|---|---|
Mar. 31, 2018 |
May 14, 2018 |
|
Document And Entity Information [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Mar. 31, 2018 | |
Document Fiscal Year Focus | 2018 | |
Document Fiscal Period Focus | Q1 | |
Entity Registrant Name | AMERICAN BIO MEDICA CORP | |
Entity Central Index Key | 0000896747 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Smaller Reporting Company | |
Trading Symbol | ABMC | |
Entity Common Stock, Shares Outstanding | 29,932,770 |
Condensed Balance Sheets (Parenthetical) - USD ($) |
Mar. 31, 2018 |
Dec. 31, 2017 |
---|---|---|
Statement of Financial Position [Abstract] | ||
Allowance For Doubtful Accounts Receivable, Current (in dollars) | $ 51,000 | $ 52,000 |
Inventory Valuation Reserves | $ 521,000 | $ 500,000 |
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 50,000,000 | 50,000,000 |
Common stock, shares issued | 29,932,770 | 29,782,770 |
Common stock, shares outstanding | 29,932,770 | 29,782,770 |
Condensed Statements of Operations - USD ($) |
3 Months Ended | |
---|---|---|
Mar. 31, 2018 |
Mar. 31, 2017 |
|
Income Statement [Abstract] | ||
Net sales | $ 1,041,000 | $ 1,316,000 |
Cost of goods sold | 669,000 | 751,000 |
Gross profit | 372,000 | 565,000 |
Operating expenses: | ||
Research and development | 25,000 | 46,000 |
Selling and marketing | 161,000 | 196,000 |
General and administrative | 392,000 | 390,000 |
Operating Expenses, Total | 578,000 | 632,000 |
Operating loss | (206,000) | (67,000) |
Other income / (expense): | ||
Interest expense | (71,000) | (65,000) |
Other income, net | 10,000 | 0 |
Other income / (expense), Total | (61,000) | (65,000) |
Net loss before tax | (267,000) | (132,000) |
Income tax expense | 0 | 0 |
Net loss | $ (267,000) | $ (132,000) |
Basic and diluted loss per common share | $ (0.01) | $ (0.00) |
Weighted average number of shares outstanding – basic | 29,822,770 | 28,842,788 |
Weighted average number of shares outstanding – diluted | 29,822,770 | 28,842,788 |
Basis of Reporting |
3 Months Ended |
---|---|
Mar. 31, 2018 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of Accounting | The accompanying unaudited interim condensed financial statements of American Bio Medica Corporation (the “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Regulation S-X. Accordingly, these unaudited interim condensed financial statements do not include all information and footnotes required by U.S. GAAP for complete financial statement presentation. These unaudited interim condensed financial statements should be read in conjunction with audited financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. In the opinion of management, the interim condensed financial statements include all normal, recurring adjustments which are considered necessary for a fair presentation of the financial position of the Company at March 31, 2018, and the results of operations and cash flows for the three month periods ended March 31, 2018 (the “First Quarter 2018”) and March 31, 2017 (the “First Quarter 2017”).
Operating results for the First Quarter 2018 are not necessarily indicative of results that may be expected for the year ending December 31, 2018. Amounts at December 31, 2017 are derived from audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.
During the First Quarter 2018, there were no significant changes to the Company’s critical accounting policies, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.
The preparation of these interim condensed financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates estimates, including those related to product returns, bad debts, inventories, income taxes, warranty obligations, contingencies and litigation. The Company bases estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
These unaudited interim condensed financial statements have been prepared assuming that the Company will continue as a going concern and, accordingly, do not include any adjustments that might result from the outcome of this uncertainty. The independent registered public accounting firm’s report on the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, contained an explanatory paragraph regarding the Company’s ability to continue as a going concern. As of the date of this report, the Company’s current cash balances, together with cash generated from future operations and amounts available under the Company’s credit facilities may not be sufficient to fund operations through May 2019. The Company’s current line of credit matures on June 29, 2020. The maximum availability on the Company’s line of credit remains to be $1,500,000. However, the amount available under the Company’s line of credit is based upon the Company’s accounts receivable and inventory. As of March 31, 2018, based on the Company’s availability calculation, there were no additional amounts available under the Company’s line of credit because the Company draws any balance available on a daily basis.
As discussed in more detail in “Cash Flow, Outlook/Risk”, if sales levels decline further, the Company will have reduced availability on its line of credit due to decreased accounts receivable balances. In addition, the Company would expect its inventory levels to decrease if sales levels decline further, and this would also result in reduced availability on the Company’s line of credit. If availability under the Company’s line of credit is not sufficient to satisfy its working capital and capital expenditure requirements, the Company will be required to obtain additional credit facilities or sell additional equity securities, or delay capital expenditures. There is no assurance that such financing will be available or that the Company will be able to complete financing on satisfactory terms, if at all.
Recently Adopted Accounting Standards
The Company adopted the following accounting standards set forth by the Financial Accounting Standards Board (“FASB”):
ASU 2014-09, “Revenue from Contracts with Customers”, issued in May 2014, provides guidance for revenue recognition. The core principle of ASU 2014-09 is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current guidance. Examples of the use of judgments and estimates may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The update also requires more detailed disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 provides for two transition methods to the new guidance: a retrospective approach and a modified retrospective approach. In August 2015, ASU 2015-14, “Revenue from Contracts with Customers: Deferral of the Effective Date” was issued as a revision to ASU 2014-09. ASU 2015-14 revised the effective date to fiscal years, and interim periods within those years, beginning after December 15, 2017. Subsequently, additional updates were issued related to this topic, ASU 2016-08, ASU 2016-10, ASU 2016-12 and ASU 2016-20. Early adoption of ASU 2014-09 is permitted but not prior to periods beginning after December 15, 2016 (i.e. the original adoption date per ASU No. 2014-09).
The Company's revenues result from the sale of goods and reflect the consideration to which the Company expects to be entitled. The Company records revenues based on a five-step model in accordance with ASU 2014-09. The Company has defined purchase orders as contracts in accordance with ASU 2014-09. For its customer contracts, the Company’s performance obligations are identified; which is delivering goods at a determined transaction price, allocation of the contract transaction price with performance obligations (when applicable), and recognition of revenue when (or as) the performance obligation is transferred to the customer. Goods are transferred when the customer obtains control of the goods (which is upon shipment to the customer). The Company's revenues are recorded at a point in time from the sale of tangible products. Revenues are recognized when products are shipped.
The Company has elected the Modified Retrospective Method (the "Cumulate Effect Method") to comply with ASU 2014-09. The Cumulative Effect Method does not affect the amounts for the prior periods, but requires that the current period be reported in accordance with ASU 2014-09. ASU 2014-09 was adopted on January 1, 2018 which was the first day of the Company's 2018 fiscal year. There was no material impact on the Company’s financial position or results of operations.
Product returns, discounts and allowances are variable consideration and are recorded as a reduction of revenue in the same period that the related sale is recorded. The Company has reviewed the overall sales transactions for variable consideration and has determined that these costs are not significant. The Company has not experienced any impairment losses, has no future performance obligations and does not capitalize costs to obtain or fulfill contracts.
Accounting Standards Issued; Not Yet Adopted
ASU 2018-02, “Income Statement – Reporting Comprehensive Income”, issued in February 2018, allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act (enacted on December 22, 2017). The amendments in ASU 2018-02 eliminate the stranded tax effects resulting from the Tax Cuts and Jobs Act and will improve the usefulness of information reported to financial statement users. However, because the amendments only relate to the reclassification of the income tax effects of the Tax Cuts and Jobs Act, the underlying guidance that requires that the effect of a change in tax laws or rates be included in income from continuing operations is not affected. The amendments in ASU 2018-02 also require certain disclosures about stranded tax effects. ASU 2018-02 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company is evaluating the impact of ASU 2018-02.
ASU 2016-02, “Leases”, issued in February 2016, requires a lessee to recognize a lease liability and a right-of-use asset on its balance sheet for all leases, including operating leases, with a term greater than 12 months. Lease classification will determine whether a lease is reported as a financing transaction in the income statement and statement of cash flows. ASU 2016-02 does not substantially change lessor accounting, but it does make certain changes related to leases for which collectability of the lease payments is uncertain or there are significant variable payments. Additionally, ASU 2016-02 makes several other targeted amendments including a) revising the definition of lease payments to include fixed payments by the lessee to cover lessor costs related to ownership of the underlying asset such as for property taxes or insurance; b) narrowing the definition of initial direct costs which an entity is permitted to capitalize to include only those incremental costs of a lease that would not have been incurred if the lease had not been obtained; c) requiring seller-lessees in a sale-leaseback transaction to recognize the entire gain from the sale of the underlying asset at the time of sale rather than over the leaseback term; and d) expanding disclosures to provide quantitative and qualitative information about lease transactions. ASU 2016-02 is effective for all annual and interim periods beginning January 1, 2019, and is required to be applied retrospectively to the earliest period presented at the date of initial application, with early adoption permitted. The Company is evaluating the impact of ASU 2016-02.
ASU 2017-11, “Earnings Per Share, Distinguishing Liabilities from Equity, Derivatives and Hedging”, issued in July 2017, changes the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature will no longer preclude equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) would not be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). ASU 2017-11 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company is evaluating the impact of ASU 2017-11.
There are no other accounting pronouncements issues during the First Quarter 2018 that are expected to have or that could have a significant impact on our financial position or results of operations.
Reclassifications
Certain items have been reclassified from the prior year to conform to the current year presentation.
|
Inventory |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2018 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory | Inventory is comprised of the following:
|
Net Loss Per Common Share |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2018 | ||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||
Net Loss Per Common Share | Basic net loss per common share is calculated by dividing the net loss by the weighted average number of outstanding common shares during the period. Diluted net loss per common share includes the weighted average dilutive effect of stock options and warrants. Potential common shares outstanding as of March 31, 2018 and 2017:
The number of securities not included in the diluted net loss per share for the First Quarter 2018 and First Quarter 2017 was 4,147,000 and 4,167,000, respectively, as their effect would have been anti-dilutive due to the net loss in the First Quarter 2018 and First Quarter 2017.
|
Litigation/Legal Matters |
3 Months Ended |
---|---|
Mar. 31, 2018 | |
Commitments and Contingencies Disclosure [Abstract] | |
Litigation/Legal Matters | ABMC v. Premier Biotech, Inc., Todd Bailey, et al.
In February 2017, the Company filed a complaint in the Supreme Court of the State of New York in Columbia County against Premier Biotech Inc., Premier Biotech Labs, LLC and its principals, including its President Todd Bailey (“Bailey”), and Peckham Vocational Industries, Inc. (together the “Defendants”). Bailey formerly served as the Company’s Vice President of Sales and Marketing and as a sales consultant until December 23, 2016. The complaint seeks preliminary and permanent injunctions and a temporary restraining order against Bailey (for his benefit or the benefit of another party or entity) related to the solicitation of Company customers as well as damages related to any profits and revenues that would result from actions taken by the Defendants related to Company customers.
In March 2017, the complaint was moved to the federal court in the Northern District of New York. In April 2017, the Defendants filed a motion to dismiss on the basis of jurisdiction, to which the Company responded on April 21, 2017.
In July 2017, the Company was notified that it was not awarded a contract with a state agency for which it has held a contract in excess of 10 years. The contract in question is included in the February 2017 complaint. The Company believes that the Defendants actions related to this customer and a RFP that was issued by the state agency resulted in the loss of the contract award to the Company and the award of the contract to Peckham and Premier Biotech. This contract historically accounted for 10-15% of the Company’s annual revenue. The Company continued to hold a contract with the agency through September 30, 2017. The Company did protest the award of the contract to Peckham and Premier Biotech, and the state agency advised the Company on July 26, 2017 that they denied the Company’s protest of the award.
The Company amended its complaint against the Defendants to show actual damages caused by the Defendants and to show proprietary and confidential information (belonging to the Company) used by the Defendants in their response to the RFP. This confidential information belonging to the Company enabled the Defendants to comply with specifications of the RFP. The Defendants filed a response to the court opposing the Company’s supplemental motion and the Company filed reply papers to the Defendants response on November 2, 2017.
In January 2018, the court ruled on the motion to dismiss (that was filed by the Defendants in April 2017). The court found that there was jurisdiction over Bailey only. In the Company’s opinion, this ruling does not diminish its standing in the case against Bailey, who again in the Company’s opinion, has always been the primary defendant. The court did not rule on the other motions before them. In February 2018, the Company filed a motion for reconsideration and for leave to serve a supplemental/amended complaint. The new filing asks for reconsideration in the jurisdiction ruling regarding Premier Biotech Inc. and addresses the Company’s intent to further supplement its complaint based on additional (subsequent) damage alleged by ABMC on the part of Bailey and Premier Biotech, Inc. Given the stage of the litigation, management is not yet able to opine on the outcome of the case.
Todd Bailey v. ABMC
On October 20, 2017, the Company received notice that Bailey, its former Vice President of Sales & Marketing and sales consultant (and the same “Bailey” discussed above) filed a complaint against the Company in the State of Minnesota seeking deferred commissions of $164,000 that Bailey alleges is owed to him by the Company. On November 2, 2017, the Company filed a Notice of Removal in this action to move the matter from state to federal court. On November 9, 2017, the Company filed a motion to dismiss or, in the alternative to transfer venue and consolidate, the Bailey complaint with our litigation filed previously against Bailey and others.
In January 2018, the judge in the Minnesota case requested additional briefing on the impact of ruling in the New York case that determined there was personal jurisdiction over Bailey. The Company filed the requested briefing as requested by the court. Given the stage of the litigation, management is not yet able to opine on the outcome of the case. As of the date of this report, the action in Minnesota has been stayed while the New York motions are decided.
|
Line of Credit and Debt |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2018 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit and Debt |
LOAN AND SECURITY AGREEMENT WITH CHEROKEE FINANCIAL, LLC (“CHEROKEE”)
On March 26, 2015, the Company entered into a LSA with Cherokee Financial, LLC (the “Cherokee LSA”). The debt with Cherokee is collateralized by a first security interest in real estate and machinery and equipment. Under the Cherokee LSA, the Company was provided the sum of $1,200,000 in the form of a 5-year Note at an annual interest rate of 8%. The Company is making interest only payments quarterly on the Cherokee LSA, with the first interest payment paid on May 15, 2015. The Company is also required to make an annual principal reduction payment of $75,000 on each anniversary of the date of the closing; with the first principal reduction payment being made on February 15, 2016 and the most recent principal reduction payment being made on February 15, 2018 with the proceeds received from a new term loan with Cherokee Financial, LLC (See “Term Loan with Cherokee” within this Note). A final balloon payment is due on March 26, 2020. In addition to the 8% interest, the Company pays Cherokee a 1% annual fee for oversight and administration of the loan. This oversight fee is paid in cash and is paid contemporaneously with the quarterly interest payments. The Company can pay off the Cherokee loan at any time with no penalty; except that a 1% administration fee would be required to be paid to Cherokee to close out all participations.
The Company received net proceeds of $80,000 after $1,015,000 of debt payments, and $105,000 in other expenses and fees. With the adoption of ASU No. 2015-03 in the First Quarter of Fiscal 2016, these transaction costs (with the exception of the interest expense) are being deducted from the balance on the Cherokee LSA and are being amortized over the term of the debt.
The Company recognized $44,000 in interest expense related to the Cherokee LSA in the First Quarter 2018 (of which $24,000 is debt issuance cost amortization recorded as interest expense), and $39,000 in interest expense in the First Quarter 2017 (of which $23,000 is debt issuance cost amortization recorded as interest expense). The Company had $12,000 in accrued interest expense at March 31, 2018 related to the Cherokee LSA.
As of March 31, 2018, the balance on the Cherokee LSA is $975,000; however the discounted balance is $779,000. As of December 31, 2017, the balance on the Cherokee LSA is $1,050,000; however the discounted balance is $847,000.
LINE OF CREDIT WITH CRESTMARK BANK (“CRESTMARK”)
On June 29, 2015 (the “Closing Date”), the Company entered into a Loan and Security Agreement (“LSA”) with Crestmark related to a revolving line of credit (the “Crestmark LOC”). The Crestmark LOC is used for working capital and general corporate purposes and expires on June 22, 2020.
The Crestmark LOC provides the Company with a revolving line of credit up to $1,500,000 (“Maximum Amount”) with a minimum loan balance requirement of $500,000. At March 31, 2018, the Company did not meet this minimum loan balance requirement as our balance was $492,000. Under the LSA, Crestmark has the right to calculate (and is calculating) interest on the minimum balance requirement rather than the actual balance on the Crestmark LOC. The Crestmark LOC is secured by a first security interest in the Company’s inventory, and receivables and security interest in all other assets of the Company (in accordance with permitted prior encumbrances).
The Maximum Amount is subject to an Advance Formula comprised of: 1) 90% of Eligible Accounts Receivables (excluding, receivables remaining unpaid for more than 90 days from the date of invoice and sales made to entities outside of the United States), and 2) up to 40% of eligible inventory plus up to 10% of Eligible Generic Packaging Components not to exceed the lesser of $350,000 (“Inventory Sub-Cap Limit”), or 100% of the Eligible Accounts Receivable.
So long as any obligations are due to Crestmark, the Company must comply with a minimum Tangible Net Worth (“TNW”) Covenant of at least $650,000. Additionally, if a quarterly net income is reported, the TNW covenant will increase by 50% of the reported net income. If a quarterly net loss is reported, the TNW covenant will remain the same as the prior quarter’s covenant amount. TNW is defined as: Total Assets less Total Liabilities less the sum of (i) the aggregate amount of non-trade accounts receivables, including accounts receivables from affiliated or related persons, (ii) prepaid expenses, (iii) deposits, (iv) net lease hold improvements, (v) goodwill and (vi) any other asset that would be treated as an intangible asset under GAAP; plus Subordinated Debt. Subordinated Debt means any and all indebtedness presently or in the future incurred by the Company to any creditor of the Company entering into a written subordination agreement with Crestmark. The Company was not in compliance with this covenant at December 31, 2017 however, the Company received a waiver from Crestmark for the December 31, 2017 TNW requirement. As consideration for the granting of the waiver, Crestmark increased the interest rate on the Crestmark LOC from current Prime Rate plus 2% to the Prime Rate plus 3%. The increase in interest rate was effective as of May 1, 2018. The Company was also not in compliance with the TNW covenant at March 31, 2018; as of the date of this report, the Company is in the process of obtaining another waiver from Crestmark. Due to internal requirements within Crestmark, the waiver could not be obtained prior to the date of this report. .. There was no additional consideration to Crestmark for the issuance of this waiver for the year ended December 31, 2017; rather the increase in interest rate will remain in place until such time that the Company is back in compliance with the TNW covenant. If the Company terminates the LSA prior to June 22, 2020, an early exit fee of 2% of the Maximum Amount (plus any additional amounts owed to Crestmark at the time of termination) would be due. In the event of a default of the LSA, which includes but is not limited to, failure of the Company to make any payment when due and non-compliance with the TNW covenant (that is not waived by Crestmark), Crestmark is permitted to charge an Extra Rate. The Extra Rate is the Company’s then current interest rate plus 12.75% per annum. As of the date of this report, Crestmark has not elected to charge the Extra Rate even though the Company is not in compliance with the TNW covenant as of March 31, 2018 as the Company expects to receive a waiver from Crestmark. Interest on the Crestmark LOC is at a variable rate based on the Prime Rate plus 2% with a floor of 5.25%. As of March 31, 2018, the interest only rate on the Crestmark LOC was 6.75%. As of March 31, 2018, with all fees considered (the interest rate + an Annual Loan Fee of $7,500 + a monthly maintenance fee of 0.30% of the actual average monthly balance from the prior month), the interest rate on the Crestmark LOC was 11.43%. With the change in the interest rate from Prime plus 2% to Prime plus 3% (as a result of Crestmark’s waiver of the Company’s non-compliance with the TNW covenant), as of the date of this report, the interest only rate is 7.75% and the rate with all fees is 12.43%. The Company recognized $21,000 in interest expense related to the Crestmark LOC in the First Quarter 2018, of which $8,000 was debt issuance costs related to interest expense. The Company recognized $26,000 in interest expense related to the Crestmark LOC in the First Quarter 2017, of which $8,000 was debt issuance costs related to interest expense. Given the nature of the administration of the Crestmark LOC, at March 31, 2018, the Company had $0 in accrued interest expense related to the Crestmark Line of Credit, and there is $0 in additional availability under the Crestmark LOC. As of March 31, 2018, the balance on the Crestmark LOC was $492,000, and as of December 31, 2017, the balance on the Crestmark LOC was $446,000. EQUIPMENT LOAN WITH CRESTMARK
On May 1, 2017, the Company entered into term loan with Crestmark in the amount of $38,000 related to the purchase of manufacturing equipment. The equipment loan is collateralized by a first security interest in a specific piece of manufacturing equipment. The Company executed an amendment to its LSA and Promissory Note with Crestmark. The amendments addressed the inclusion of the term loan into the LSA and an extension of the Crestmark LOC. No terms of the Crestmark LOC were changed in the amendment. The interest rate on the term loan is the WSJ Prime Rate plus 3%; or 7.75% as of the date of this report. The balance on the equipment loan was $28,000 as of March 31, 2018, and $31,000 as of December 31, 2017. The Company incurred less than $1,000 in interest expense related to the Equipment Loan in First Quarter 2018 and $0 in interest expense in the First Quarter 2017 (as the Equipment Loan was not yet in place). Given the Company has not yet received the waiver for the TNW compliance at March 31, 2018, the Company is in default under the Equipment Loan with Crestmark as of the date of this report. This results in the Equipment Loan being due and payable if called by Crestmark.
TERM LOAN WITH CHEROKEE
On March 2, 2018, the Company entered into a one-year Loan Agreement made as of February 15, 2018 (the “Closing Date”) with Cherokee under which Cherokee provided the Company with $150,000 (the “Cherokee Term Loan”). The proceeds from the Cherokee Term Loan were used by the Company to pay a $75,000 principal reduction payment to Cherokee and $1,000 in legal fees incurred by Cherokee. Net proceeds (to be used for working capital and general business purposes) were $74,000.
The annual interest rate for the Cherokee Term Loan is 12% to be paid quarterly in arrears with the first interest payment being due on May 15, 2018. The Cherokee Term Loan is required to be paid in full on February 15, 2019 unless paid off earlier (with no penalty) at the Company’s sole discretion. In connection with the Cherokee Term Loan, the Company issued 150,000 restricted shares of common stock to Cherokee on March 8, 2018.
In the event of default, this includes, but is not limited to, the Company’s inability to make any payments due under the Cherokee Term Loan, Cherokee has the right to increase the interest rate on the Cherokee Term Loan to 18% and the Company would be required to issue and additional 150,000 restricted shares of common stock to Cherokee.
The Company recognized $5,000 in interest expense related to the Cherokee Term Loan in the First Quarter 2018, of which $3,000 was debt issuance costs related to interest expense, and $0 in interest expense in the First Quarter 2017 (as the Cherokee Term Loan was not yet in place). The balance on the Cherokee Term Loan was $150,000 at March 31, 2018 and $0 at December 31, 2017 (as the Cherokee Term Loan was not yet in place).
|
Stock Options and Warrants |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity Note [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Options and Warrants | The Company currently has two non-statutory stock option plans, the Fiscal 2001 Non-statutory Stock Option Plan (the “2001 Plan”) and the 2013 Equity Compensation Plan (the “2013 Plan”). Both plans have been adopted by our Board of Directors and approved by our shareholders. Both the 2001 Plan and the 2013 Plan have options available for future issuance. Any common shares issued as a result of the exercise of stock options would be new common shares issued from our authorized issued shares.
During the First Quarter 2018 and the First Quarter 2017, the Company issued 0 options to purchase shares of common stock.
Stock option activity for the First Quarter 2018 and the First Quarter 2017 is summarized as follows (the figures contained within the tables below have been rounded to the nearest thousand):
The Company recognized $4,000 in share based payment expense in the First Quarter 2018 and $11,000 in share based payment expense in the First Quarter 2017. At March 31, 2018 there was approximately $2,000 of total unrecognized share based payment expense related to stock options. This cost is expected to be recognized over 2 months.
Warrants
Warrant activity for the First Quarter 2018 and the First Quarter 2017 is summarized as follows:
In the First Quarter 2018 and First Quarter 2017, the Company recognized $0 in debt issuance and deferred finance costs related to the issuance of the above warrants outstanding. As of March 31, 2018, there was $0 of total unrecognized expense.
|
Basis of Reporting (Policies) |
3 Months Ended |
---|---|
Mar. 31, 2018 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Recently Adopted Accounting Standards | The Company adopted the following accounting standards set forth by the Financial Accounting Standards Board (“FASB”):
ASU 2014-09, “Revenue from Contracts with Customers”, issued in May 2014, provides guidance for revenue recognition. The core principle of ASU 2014-09 is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current guidance. Examples of the use of judgments and estimates may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The update also requires more detailed disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 provides for two transition methods to the new guidance: a retrospective approach and a modified retrospective approach. In August 2015, ASU 2015-14, “Revenue from Contracts with Customers: Deferral of the Effective Date” was issued as a revision to ASU 2014-09. ASU 2015-14 revised the effective date to fiscal years, and interim periods within those years, beginning after December 15, 2017. Subsequently, additional updates were issued related to this topic, ASU 2016-08, ASU 2016-10, ASU 2016-12 and ASU 2016-20. Early adoption of ASU 2014-09 is permitted but not prior to periods beginning after December 15, 2016 (i.e. the original adoption date per ASU No. 2014-09).
The Company's revenues result from the sale of goods and reflect the consideration to which the Company expects to be entitled. The Company records revenues based on a five-step model in accordance with ASU 2014-09. The Company has defined purchase orders as contracts in accordance with ASU 2014-09. For its customer contracts, the Company’s performance obligations are identified; which is delivering goods at a determined transaction price, allocation of the contract transaction price with performance obligations (when applicable), and recognition of revenue when (or as) the performance obligation is transferred to the customer. Goods are transferred when the customer obtains control of the goods (which is upon shipment to the customer). The Company's revenues are recorded at a point in time from the sale of tangible products. Revenues are recognized when products are shipped.
The Company has elected the Modified Retrospective Method (the "Cumulate Effect Method") to comply with ASU 2014-09. The Cumulative Effect Method does not affect the amounts for the prior periods, but requires that the current period be reported in accordance with ASU 2014-09. ASU 2014-09 was adopted on January 1, 2018 which was the first day of the Company's 2018 fiscal year. There was no material impact on the Company’s financial position or results of operations.
Product returns, discounts and allowances are variable consideration and are recorded as a reduction of revenue in the same period that the related sale is recorded. The Company has reviewed the overall sales transactions for variable consideration and has determined that these costs are not significant. The Company has not experienced any impairment losses, has no future performance obligations and does not capitalize costs to obtain or fulfill contracts.
|
Accounting Standards Issued; Not Yet Adopted | ASU 2018-02, “Income Statement – Reporting Comprehensive Income”, issued in February 2018, allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act (enacted on December 22, 2017). The amendments in ASU 2018-02 eliminate the stranded tax effects resulting from the Tax Cuts and Jobs Act and will improve the usefulness of information reported to financial statement users. However, because the amendments only relate to the reclassification of the income tax effects of the Tax Cuts and Jobs Act, the underlying guidance that requires that the effect of a change in tax laws or rates be included in income from continuing operations is not affected. The amendments in ASU 2018-02 also require certain disclosures about stranded tax effects. ASU 2018-02 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company is evaluating the impact of ASU 2018-02.
ASU 2016-02, “Leases”, issued in February 2016, requires a lessee to recognize a lease liability and a right-of-use asset on its balance sheet for all leases, including operating leases, with a term greater than 12 months. Lease classification will determine whether a lease is reported as a financing transaction in the income statement and statement of cash flows. ASU 2016-02 does not substantially change lessor accounting, but it does make certain changes related to leases for which collectability of the lease payments is uncertain or there are significant variable payments. Additionally, ASU 2016-02 makes several other targeted amendments including a) revising the definition of lease payments to include fixed payments by the lessee to cover lessor costs related to ownership of the underlying asset such as for property taxes or insurance; b) narrowing the definition of initial direct costs which an entity is permitted to capitalize to include only those incremental costs of a lease that would not have been incurred if the lease had not been obtained; c) requiring seller-lessees in a sale-leaseback transaction to recognize the entire gain from the sale of the underlying asset at the time of sale rather than over the leaseback term; and d) expanding disclosures to provide quantitative and qualitative information about lease transactions. ASU 2016-02 is effective for all annual and interim periods beginning January 1, 2019, and is required to be applied retrospectively to the earliest period presented at the date of initial application, with early adoption permitted. The Company is evaluating the impact of ASU 2016-02.
ASU 2017-11, “Earnings Per Share, Distinguishing Liabilities from Equity, Derivatives and Hedging”, issued in July 2017, changes the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature will no longer preclude equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) would not be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). ASU 2017-11 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company is evaluating the impact of ASU 2017-11.
There are no other accounting pronouncements issues during the First Quarter 2018 that are expected to have or that could have a significant impact on our financial position or results of operations.
|
Reclassification, Policy [Policy Text Block] | Certain items have been reclassified from the prior year to conform to the current year presentation.
|
Inventory (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2018 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Inventory, Current |
|
Net Loss Per Common Share (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2018 | ||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Earnings Per Share, Basic and Diluted |
|
Line of Credit and Debt (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2018 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Long-term Debt |
|
Stock Options and Warrants (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Employee Stock Option [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] |
|
Inventory (Details) - USD ($) |
Mar. 31, 2018 |
Dec. 31, 2017 |
---|---|---|
Inventory Disclosure [Abstract] | ||
Raw Materials | $ 1,004,000 | $ 1,023,000 |
Work In Process | 407,000 | 403,000 |
Finished Goods | 498,000 | 547,000 |
Allowance for slow moving and obsolete inventory | (521,000) | (500,000) |
Inventory, Net, Total | $ 1,388,000 | $ 1,473,000 |
Net Loss Per Common Share (Details) - shares |
3 Months Ended | |
---|---|---|
Mar. 31, 2018 |
Mar. 31, 2017 |
|
Weighted Average Number Diluted Shares Outstanding Adjustment | 4,147,000 | 4,167,000 |
Warrant [Member] | ||
Weighted Average Number Diluted Shares Outstanding Adjustment | 2,000,000 | 2,060,000 |
Employee Stock Option [Member] | ||
Weighted Average Number Diluted Shares Outstanding Adjustment | 2,147,000 | 2,107,000 |
Net Loss Per Common Share (Details Narrative) - shares |
3 Months Ended | |
---|---|---|
Mar. 31, 2018 |
Mar. 31, 2017 |
|
Earnings Per Share [Abstract] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 4,147,000 | 4,167,000 |
Line of Credit and Debt (Details) - USD ($) |
Mar. 31, 2018 |
Dec. 31, 2017 |
---|---|---|
Debt Instrument [Line Items] | ||
Long-term Debt, Gross | $ 1,645,000 | $ 1,527,000 |
Less debt discount & issuance costs (Cherokee Financial, LLC Loan) | (196,000) | (203,000) |
Total debt, net | 1,449,000 | 1,324,000 |
Current portion | 729,000 | 533,000 |
Long-term portion, net of current portion | 720,000 | 791,000 |
Cherokee Financial LLC [Member] | ||
Debt Instrument [Line Items] | ||
Long-term Debt, Gross | 975,000 | 1,050,000 |
Crestmark Line of Credit [Member] | ||
Debt Instrument [Line Items] | ||
Long-term Debt, Gross | 492,000 | 446,000 |
Crestmark Equipment Term Loan [Member] | ||
Debt Instrument [Line Items] | ||
Long-term Debt, Gross | 28,000 | 31,000 |
Cherokee Financial LLC [Member] | ||
Debt Instrument [Line Items] | ||
Long-term Debt, Gross | $ 150,000 | $ 0 |
Stock Options and Warrants (Details) - Employee Stock Option [Member] - USD ($) |
3 Months Ended | |
---|---|---|
Mar. 31, 2018 |
Mar. 31, 2017 |
|
Shares, Beginning Balance | 2,147,000 | 2,107,000 |
Shares, Exercised | 0 | 0 |
Shares, Cancelled/expired | 0 | 0 |
Shares, Ending Balance | 2,147,000 | 2,107,000 |
Exercisable at end of period | 2,022,000 | 1,485,000 |
Weighted Average Exercise Price, at beginning of period | $ 0.13 | $ 0.13 |
Weighted Average Exercise Price, at end of period | 0.13 | 0.13 |
Weighted Average Exercise Price, Exercisable, at end of period | $ 0.13 | $ 0.13 |
Aggregate Intrinsic Value, Outstanding at end of period | $ 15,000 | $ 15,000 |
Stock Options and Warrants (Details 1) - Warrant [Member] - $ / shares |
3 Months Ended | |
---|---|---|
Mar. 31, 2018 |
Mar. 31, 2017 |
|
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Shares, Beginning Balance | 2,060,000 | 2,060,000 |
Shares, Exercised | 0 | 0 |
Shares, Cancelled/expired | 60,000 | 0 |
Shares, Ending Balance | 2,000,000 | 2,060,000 |
Exercisable at end of period | 2,000,000 | 2,060,000 |
Weighted Average Exercise Price, at beginning of period | $ 0.18 | $ 0.18 |
Weighted Average Exercise Price, at end of period | 0.18 | 0.18 |
Weighted Average Exercise Price, Exercisable, at end of period | $ 0.18 | $ 0.18 |
Stock Options and Warrants (Details Narrative) - USD ($) |
3 Months Ended | |
---|---|---|
Mar. 31, 2018 |
Mar. 31, 2017 |
|
Stockholders' Equity Note [Abstract] | ||
Share based payment expense | $ 4,000 | $ 11,000 |
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
;.6I5P#V/![1F.M=(^"RCB"?-TI1+[U]=>[!
M0;%(?SEXUK2^.3:K(";7LD"SUF'YL\>CV0LP)ZP+PD7#(\M")QM6J#+ATL85
MRXOY_5E8K0+&2A %,E.$Q\ECB"ADOG)3G)BY=[S? ?0T _UMP5M2+%X:A0D;5F3=IR?\/V=TY&4W=TK6L%\Q9#
MUP7X:I1D'=F VT% VPEU0_:K(/O312H%-IV 2O1BO;< 3N_]O(J5K;-W]<+P
M^[(L ?]!/:X_?SO[2O">??U@77T\__W[Q?7_6&>_??_X\ 643,#?SLXNW[%D!SD;XN7SMB(,
MO$ZUG?O9PI_ $+4#9B**JA.988!2N %N ZPY!JCQ5#C21])I L8:DED:1=G=
MN8J]2,T^2@,\C"29YB+!Y&[*\VCT"^\C-*@"U-02/(R#VH7&E8J;\R%0M(51
M*>'I'O*TEUEJ9%]GE)E(1&2A+@[4RK!57DCH\QF SL839J:3S')%I8X?C(^'
M9&^8R11CPZNI/;P86U^*I;Z_ :N1+B>7[,RSF6:\XGLW?Y3"I_TE-C9#JE)@
MB]VJ>Z]AA[0A/=[+FK&K9 1L!E51U:IVL *
MSC&X0*GK75WI=62!:R],? 23,]%/:!$0=,<4T!_?[.VC
M!8W$'#NV@Q3^T
MK"N048-WUM".;KS@K=5Y9^$4>[;OW<"?_TS!+AX\RA^]P!4X7J=]Z 6O_NLF
M>7=]*RP; !R.[ [_ &N[!2TL'#_ZW]U]]]YR/W>$ %WD7A=:\ 6H.T#A+)W
M?VR% ^ML""\Z=F"]]T+K"RARQ[;.PV@4
&*]]
M#HT;E)XD/#IWR>?[+^?67=NZC,30 Z2_]\)$.+>\WQ>!TX8)0]>UWF-OV\>6
M);"=.^]*6N+W/T<6O
;% =-?MT?T'(S1@@B =SKS>/A^G@F41
M&,(73A[J1('):@JW"WX+TYO;HI29: 84%8Q46KG#4#9Q\V8*&'H.R/PD5.;
M)&O@&?)'+E&PQ,C =+XI]WJ5&1=CEWH-^%(O12IE@=/QC,7)=@^JSB.DPDD#
M\NR@PS M1NM5 'AGW++Z/Q0LXIQ$.@_Y)/.P* D1X\GXRHRKQC(O3<9&;: =
M^T;HSU2L5 >#C&O'=O,8(+ F[P&%!^-Y?3MFBD#YR.-@
M;3_'_/PFC?=N;'OT%A-&/X B!JL^C<0U4/I['X3&K__Y']@+[F?UVA5*$LQ]
M%5&,D87D$4-U)1]R]Y6'Y+L8_/+JLM/]$_Z#F+X..Z=_[G?HWZ]^72N?FG$K
MF>SB4XB'Y>M]2,?8V DJI7H&EIJRH09L.28+,U7+AAF=KO4U]P5AQ_K&7US"
M%V,N#'V$3W*YYDH# %+V"1A&+4$+_&1/&Z^[/S9>VWH?8C$3@@SKN\-N&@*/
MSV M[(&$:03OV)%+(3[0,0[ S[54]HCRF?$UMIK@55(HA,
MTY\RY$A4R<:I:LAQC8GFJ;B7]BEV3P58Z=/8U"7, E/@9N6;*2T)3"S#>8P)
M6!LR6 QH!:9W[" 9AP=?0$LB\@3@"W OR-9>A%)=?";8MPR?M4:I.@$3=:\
M&%^4?,TJQ1YY">SKOU68$40&:Q
SX9BPMORO$I2Z/YIJL+R(HH/NYUE@"R
MC"?.^>W%P]O[^Q/Y38Z]T/25$3*9W;/I?W[ST(]\[RW^-_SY_P-02P,$%
M @ P8JN3-J^,3]\" <$0 !$ !A8FUC+3(P,3@P,S,Q+GAS9.U<6W,J
M-Q)^WJW:_Z!0M579AS$,V#XVL9.RL9TEP9<8)^>L7U)B1H#*,](<26/#OT]K
M;L!
9WV;YV#
MYR$^\H(D^'_QX;^[%^WW^*US]-!MG[S_=-(^^I_APQ*2S.+5P]K/[>QK(?XY
MI-'W$_%M0&+PT)!1?/(U@=M\*IZ%W
M;E2)"C,.:?Q9F"9:Z$K?"Q)8"V#V'BSK$?"W&+3BQT(^FUKH>$UO*97_%6OP
M%E5XA3IJ@:T9DQ8 =Q'E:A"#OZ]DO4S8RZ0SH$NH(?,+\$(QZ$,73JS
M,"3Q()U>F,7-$2'3%C+_L05A$B\_$;[PL=GN9+,,/V4?_]6+8P1P/N,\EWN%
M9 !A^MB_LG)KQ5KV (N!(!(N?ES^F-%'$HH!8B\Y1W^>8[:63DC)%3$47U3@]&M=:Y\^B+MTJI21507"674T*;NJ-3?Z-"7X_#-37:W&^&8C7K?L;\P
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M@AQZ7!HGPD51)3L$(:Y)P"Y973W.IYFJ2)W?^R*!$E;5_*U?@FAX%:)NDY